NBP NovaBridge Biosciences (NBP) H1 FY26 earnings call
NovaBridge Biosciences, under new CEO Srishti Gupta, presented its H1 FY26 results, emphasizing a differentiated strategy to advance promising medicines. The company is focused on its lead oncology program, givastomig, which is progressing towards Phase III, and its ophthalmology program, VIS-101, through its majority-owned subsidiary Visara. The strategy involves disciplined capital allocation and leveraging BD and clinical development expertise to bring innovative therapies to market, with a particular focus on European market gaps and women's health.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.